|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin
McWilliam and his colleagues examine how genetic information can be used to avoid adverse reactions from prescription drugs and model the resultant savings from lower injury rates.
Progress towards realizing a vision of personalized medicine—drugs and drug doses that are safer and more effective because they are chosen based on an individual's genetic makeup—has been slower than once forecast. The Food and Drug Administration has a key role to play in facilitating the use of genetic information in drug therapies because it approves labels, and labels influence how doctors use drugs. Here we evaluate one example of how using genetic information in drug therapy may improve public health and lower health care costs.
|home spotlight commentary research events news about contact links archives|